title: The effect of salmeterol on the early- and late-phase reaction to bronchial allergen and postchallenge variation in bronchial reactivity, blood eosinophils, serum eosinophil cationic protein, and serum eosinophil protein X.
abstract: The late asthmatic response to bronchial allergen challenge and the associated increase in nonspecific bronchial reactivity provides a model for studying the acute inflammatory mechanisms in asthmatic airways. In 12 asthmatic patients (aged 22-37 years) with known dual reaction to allergen challenge, salmeterol 50 micrograms, 100 micrograms, or placebo was administered as a single dose 10 min before allergen challenge in a double-blind, randomized order on three different study days 2 weeks apart. The bronchial reactivity (BH) to histamine was measured the day before and 24 and 48 h after allergen challenge. Salmeterol significantly inhibited the early (P < 0.02) and the late (P < 0.05) asthmatic reactions. After placebo, mean BH was significantly increased above base line at 24 and 48 h (P < 0.02). After 50 and 100 micrograms salmeterol, BH was less than base line at 24 h and returned to prechallenge values at 48 h. Blood eosinophils increased significantly (P < 0.05) 24 and 48 h after allergen challenge, and no difference was found between treatments. After pretreatment with placebo, serum eosinophil cationic protein (s-ECP) and serum eosinophil protein X (s-EPX) increased significantly (P < 0.05) 24 and 48 h after allergen challenge. After treatment with salmeterol 50 micrograms, s-EPX, but not s-ECP, increased significantly 24 h after challenge, but was normal at 48 h. After salmeterol 100 micrograms, no change in s-EPX or s-ECP was found. The results showed that salmeterol eliminated the allergen-induced dual asthmatic reaction and gave protection against increased BH.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Respiratory Diseases, University Hospital of Aarhus, Denmark.
authors.forename: B
authors.initials: B
authors.lastname: Pedersen
authors.forename: R
authors.initials: R
authors.lastname: Dahl
authors.forename: B B
authors.initials: BB
authors.lastname: Larsen
authors.forename: P
authors.initials: P
authors.lastname: Venge
mesh_terms: D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000328:Adult; D000420:Albuterol / Q000031:analogs & derivatives* / Q000494:pharmacology; D000485:Allergens; D001249:Asthma / Q000097:blood* / Q000503:physiopathology*; D001798:Blood Proteins / Q000032:analysis*; D001985:Bronchial Provocation Tests; D004311:Double-Blind Method; D047091:Eosinophil Granule Proteins; D047208:Eosinophil-Derived Neurotoxin; D004804:Eosinophils; D005260:Female; D005541:Forced Expiratory Volume; D006632:Histamine; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D012260:Ribonucleases; D000068299:Salmeterol Xinafoate
chemical_list: D000318:Adrenergic beta-Agonists; D000485:Allergens; D001798:Blood Proteins; D047091:Eosinophil Granule Proteins; D000068299:Salmeterol Xinafoate; D006632:Histamine; D047208:Eosinophil-Derived Neurotoxin; D012260:Ribonucleases; D000420:Albuterol